Russell Lewis

Russell Lewis

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GCGeorgios Chamilos
Georgios Chamilos
RLRussell Lewis
Russell Lewis
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
Background. Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis.Methods. We analyzed

15 April 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
MLMichail S. Lionakis
Michail S. Lionakis
RLRussell Lewis
Russell Lewis
GCGeorgios Chamilos
Georgios Chamilos
MHMimi Healy
Mimi Healy
IRIssam I. Raad
Issam I. Raad
BackgroundAnecdotal evidence suggests a rise in zygomycosis in association with voriconazole (VRC) use in immunosuppressed patientsMethodsWe performe

22 June 2020 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
PVPaul Verweij
Paul Verweij
BRBart Rijnders
Bart Rijnders
RBRoger J. M. Brüggemann
Roger J. M. Brüggemann
EAElie Azoulay
Elie Azoulay
MBMatteo Bassetti
Matteo Bassetti
FVFrank van de Veerdonk
Frank van de Veerdonk
Purpose Invasive pulmonary aspergillosis is increasingly reported in patients with influenza admitted to the intensive care unit (ICU). Classification of patients with influenza-associated pulmonary aspergillosis (IAPA) using the current definitions for invasive fungal diseases has proven difficult, and our aim was to develop case definitions for IAPA that can facilitate clinical studies. Methods A group of 29 international experts reviewed current insights into the epidemiology, diagnosis and management of IAPA and proposed a case definition of IAPA through a process of informal consensus. Results Since IAPA may develop in a wide range of hosts, an entry criterion was proposed and not host factors. The entry criterion was defined as a patient requiring ICU admission for respiratory distress with a positive influenza test temporally related to ICU admission. In addition, proven IAPA required histological evidence of invasive septate hyphae and mycological evidence for Aspergillus. Probable IAPA required the detection of galactomannan or positive Aspergillus culture in bronchoalveolar lavage (BAL) or serum with pulmonary infiltrates or a positive culture in upper respiratory samples with bronchoscopic evidence for tracheobronchitis or cavitating pulmonary infiltrates of recent onset. The IAPA case definitions may be useful to classify patients with COVID-19-associated pulmonary aspergillosis (CAPA), while awaiting further studies that provide more insight into the interaction between Aspergillus and the SARS-CoV-2-infected lung. Conclusion A consensus case definition of IAPA is proposed, which will facilitate research into the epidemiology, diagnosis and management of this emerging acute and severe Aspergillus disease, and may be of use to study CAPA.

1 April 2011 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
MGMarisa Zenaide Ribeiro Gomes
Marisa Zenaide Ribeiro Gomes
RLRussell Lewis
Russell Lewis
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
SUMMARY: Rhizopus,Mucor, andLichtheimia(formerlyAbsidia) species are the most common members of the order Mucorales that cause mucormycosis, accounting for 70 to 80% of all cases. In contrast,Cunninghamella,Apophysomyces,Saksenaea,Rhizomucor,Cokeromyces,Actinomucor, andSyncephalastrumspecies individually are responsible for fewer than 1 to 5% of reported cases of mucormycosis. In this review, we provide an overview of the epidemiology, clinical manifestations, diagnosis of, treatment of, and prognosis for unusual Mucormycetes infections (non-Rhizopus, -Mucor, and -Lichtheimiaspecies). The infections caused by these less frequent members of the order Mucorales frequently differ in their epidemiology, geographic distribution, and disease manifestations.Cunninghamella bertholletiaeandRhizomucor pusillusaffect primarily immunocompromised hosts, mostly resulting from spore inhalation, causing pulmonary and disseminated infections with high mortality rates.R. pusillusinfections are nosocomial or health care related in a large proportion of cases. WhileApophysomyces elegansandSaksenaea vasiformisare occasionally responsible for infections in immunocompromised individuals, most cases are encountered in immunocompetent individuals as a result of trauma, leading to soft tissue infections with relatively low mortality rates. Increased knowledge of the epidemiology and clinical presentations of these unusual Mucormycetes infections may improve early diagnosis and treatment.

1 March 2002 in The Lancet
Verified
Journal Article
Closed access
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
RLRussell Lewis
Russell Lewis

4 August 2011 in Blood
Verified
Journal Article
Open access
PDF file
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
RLRussell Lewis
Russell Lewis
Unlike invasive aspergillosis, the prognosis and outcome of hematologic malignancy patients who develop invasive mucormycosis have not significantly improved over the past decade as a majority of patients who develop the infection still die 12 weeks after diagnosis. However, early recognition and treatment of invasive mucormycosis syndromes, as well as individualized approaches to treatment and secondary prophylaxis, could improve the odds of survival, even in the most persistently immunosuppressed patient receiving chemotherapy and/or of stem cell transplantation. Herein, we describe the subtle clinical and radiographic clues that should alert the hematologist to the possibility of mucormycosis, and aggressive and timely treatment approaches that may limit the spread of infection before it becomes fatal. Hematology patients with this opportunistic infection require integrated care across several disciplines and frequently highly individualized and complex sequence of decision-making. We also offer perspectives for the use of 2 antifungals, amphotericin B products and posaconazole, with activity against Mucorales. The availability of posaconazole in an oral formulation that can be administered safely for prolonged periods makes it an attractive agent for long-term primary and secondary prophylaxis. However, serum drug concentration monitoring may be required to minimize breakthrough infection or relapsing mucormycosis associated with inadequate blood concentrations.